Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    MK-3102
Show Display Options
Rank Status Study
1 Completed A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: January 2016
2 Completed A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: January 2013
Primary Completion: March 2016
3 Completed
Has Results
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: MK-3102
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: January 2013
Primary Completion: March 2013
4 Completed
Has Results
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
Conditions: Chronic Renal Insufficiency;   Type 2 Diabetes Mellitus
Intervention: Drug: Omarigliptin
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: August 2011
Primary Completion: March 2012
5 Terminated
Has Results
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Glimepiride;   Drug: Omarigliptin Placebo;   Drug: Glimepiride Placebo
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: July 2013
Primary Completion: April 2014
6 Completed
Has Results
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)
Condition: Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo to omarigliptin;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: May 2013
Primary Completion: September 2015
7 Completed
Has Results
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo to Omarigliptin;   Drug: Glimepiride;   Drug: Glimepiride Placebo;   Drug: Metformin;   Drug: Insulin Glargine
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: September 2012
Primary Completion: January 2015
8 Completed
Has Results
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
Condition: Type 2 Diabetes (T2D)
Interventions: Drug: Omarigliptin;   Drug: Placebo
Phase: Phase 1
Sponsor: Merck Sharp & Dohme Corp.
Study Start: March 2010
Primary Completion: May 2010
9 Completed
Has Results
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo to omarigliptin;   Drug: Pioglitazone;   Drug: Metformin;   Drug: Placebo to metformin
Phase: Phase 2
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2010
Primary Completion: January 2012
10 Completed
Has Results
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo to Omarigliptin;   Drug: Metformin;   Drug: Placebo to metformin;   Drug: Glimepiride
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: December 2012
Primary Completion: June 2015
11 Not yet recruiting Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo;   Biological: Insulin
Phase: Phase 4
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2016
Primary Completion: August 2018
12 Completed
Has Results
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Sitagliptin;   Drug: Placebo to omarigliptin;   Drug: Placebo to sitagliptin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: April 2014
13 Terminated A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Placebo
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: May 2016
14 Completed
Has Results
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Matching placebo to omarigliptin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: May 2014
15 Completed
Has Results
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Condition: Type 2 Diabetes
Interventions: Drug: Omarigliptin;   Drug: Sitagliptin;   Drug: Placebo to omarigliptin;   Drug: Placebo to Sitagliptin;   Drug: Open-label Metformin;   Drug: Open-label Glimepiride
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: June 2013
Primary Completion: November 2014
16 Completed
Has Results
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Omarigliptin;   Drug: Matching placebo to Omarigliptin;   Drug: Glimepiride;   Drug: Metformin
Phase: Phase 3
Sponsor: Merck Sharp & Dohme Corp.
Study Start: October 2012
Primary Completion: December 2014

Indicates status has not been verified in more than two years